Request Demo

Last update 08 May 2025

ScpA

Last update 08 May 2025

Basic Info

Synonyms-

Introduction-

Drugs associated with ScpA

VAX-A1

Target

ScpA

Mechanism

ScpA inhibitors [+1]

Active Org.-

Originator Org.

Vaxcyte, Inc.

Active Indication-

Inactive Indication

Streptococcal Infections

Drug Highest PhasePending

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with ScpA

100 Translational Medicine associated with ScpA

0 Patents (Medical) associated with ScpA

168

Literatures (Medical) associated with ScpA

01 Jul 2025·Metabolic Engineering

Engineering Halomonas bluephagenesis for pilot production of terpolymers containing 3-hydroxybutyrate, 4-hydroxybutyrate and 3-hydroxyvalerate from glucose

Article

Author: Yang, Shimao ; Jer, Ng Wuh ; Zheng, Shuang ; Hu, Qitiao ; Chen, Guo-Qiang ; Sun, Simian ; Zhang, Zhongnan ; Wu, Fuqing ; Wu, Qiong ; Xu, Geyuan ; He, Hongtao

Microbial poly(3-hydroxybutyrate-co-4-hydroxybutyrate-co-3-hydroxyvalerate), abbreviated as P(3HB-4HB-3HV) or P34HBHV, is a flexible polyhydroxyalkanoate (PHA) material ranging from softness to elasticity depending on the ratios of various monomers. Halomonas bluephagenesis, as the chassis of the next generation industrial biotechnology (NGIB) able to grow contamination free under open unsterile conditions. The resulting recombinants of H. bluephagenesis became capable of efficiently synthesizing P34HBHV utilizing glucose as the sole carbon source. Engineered H. bluephagenesis H1 (encoding ogdA, sucD, 4hbD, orfZ, scpA and scpB in chromosomes) transformed with a plasmid containing PHA synthesis genes phaC and phaA and its derivative H29 produced up to 92 % P(3HB-co-8.85 %4HB-co-8.47 %3HV) and 72 % P(3HB-co-13.21 %4HB-co-11.97 %3HV) in cell dry weight (CDW), respectively, in shake flasks. In bioreactor cultivation, H. bluephagenesis H39 constructed by integrating the 4hbD, phaC and phaA genes into the genome of H. bluephagenesis H1 achieved 95 g/L CDW with 69 % P(3HB-co-10.49 %4HB-co-3.54 %3HV), while H. bluephagenesis H43, further optimized with lpxM deletion, reached 73 g/L CDW with 78 % P(3HB-co-10.35 %4HB-co-4.54 %3HV) in a 100 L bioreactor. For the first time, H. bluephagenesis was successfully engineered to generate stable and hyperproductive derivative strains for pilot production of P(3HB-4HB-3HV) with customizable monomer ratios from glucose as the sole carbon source.

15 Apr 2025·The Journal of Infectious Diseases

Serological Responses to Target Streptococcus pyogenes Vaccine Antigens in Patients With Proven Invasive β-Hemolytic Streptococcal Infections

Article

Author: Smith, Rosemary ; Fulurija, Alma ; Taggart, Michael ; Morici, Michael ; Levy, Avram ; Langworthy, Kristyn ; Hui, Siong ; Knight, Daniel R ; Raby, Edward ; Manning, Laurens

AbstractBackgroundRising incidence of invasive β-hemolytic streptococcal (iBHS) infections has prompted consideration of vaccination as a preventative strategy for at-risk populations. The benefits of a vaccine targeting Lancefield group A (Streptococcus pyogenes; Strep A) would increase if cross-species immunity against Lancefield groups C/G (Streptococcus dysgalactiae subspecies equisimilis; SDSE) and B (Streptococcus agalactiae; GBS) was demonstrated.MethodsA prospective, observational study of adult patients with iBHS infections due to Strep A, SDSE, or GBS. Antibody responses to 6 Strep A candidate antigens were assayed on acute and convalescent sera. A serological response was defined as an increase of >0.2 log10 arbitrary units/mL (AU/mL).ResultsSixty-seven participants were enrolled. Thirty-three participants were included in the final analysis (12, 11, and 10 with Strep A, SDSE, and GBS, respectively). The median serological response for participants with Strep A was significant for all tested antigens (median >0.2 log10 difference between acute and convalescent samples; P < .05 for all). Those with SDSE had comparable and significant median responses to streptolysin-O (0.65 log10 AU/mL; interquartile range [IQR], 0.36–1.67; P = .004), S. pyogenes adhesion and division protein (0.68 log10 AU/mL; IQR, 0.36–1.63; P = .005), and C5a peptidase (ScpA; 0.30 log10 AU/mL; IQR, 0.23–1.06; P = .004). GBS responses were limited to ScpA only (0.34 log10 AU/mL; IQR, 0.08–0.52; P = .05).ConclusionsPatients with invasive Strep A infection mount robust antibody responses to 6 non-M protein vaccine candidate antigens. Similar significant responses to C5a peptidase in those with invasive SDSE and GBS infection highlight the importance of further research into cross-species protection and immunological correlates of vaccine efficacy.

01 Feb 2025·International Journal of Pharmaceutics

An in-situ forming controlled release soft hydrogel-based C5a peptidase drug delivery system to treat psoriasis

Article

Author: Duarte, Francisco ; Tecza, Malgorzata ; McGourty, Kieran ; Patel, Pratikkumar ; Bhattacharjee, Promita ; Hudson, Sarah ; Gedi, Vinayakumar

The potent pro-inflammatory cytokine, interferon gamma (IFN-γ), is an enticing therapeutic target because of its accelerator role in several acute and chronic inflammatory processes. In this work, poloxamer 407 is developed as an in-situ gelling polymer for a long-acting formulation to deliver a serine protease, C5a peptidase (ScpA) from Streptococcus pyogenes. ScpA is well known for its activity against the complement factor C5a but has also recently been shown to cleave IFN-γ in vitro into inactive fragments. A compact and uniform gel microstructure was obtained by including dextran in the gel formulation. The sol-gel transition at physiologically temperatures occurred above 19 % w/w poloxamer 407 resulting in a release profile of active ScpA for up to 8 days, with no loss in specific enzymatic activity. No cytotoxicity from ScpA before or after release from the hydrogels to a human immortalized keratinocyte cell lines was detected. Using an in vitro psoriatic skin model with IFN- γ inducing the psoriatic state, the constant and prolonged release of ScpA from this simple thermo-responsive hydrogel, administered once, restored health as effectively as two doses of free enzyme over a 5 day period. These promising results confirm the feasibility of developing ScpA as a long-acting therapeutic using a poloxamer based in-situ forming parenteral gel for local delivery.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

ScpA

Basic Info

Related

Analysis